country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-151255

Copy Link Print Information

CDK8-IN-9

CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor with an IC₅₀ value of 48.6 nM. CDK8-IN-9 can inhibit tumor growth and is used in colorectal cancer studies.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2850253-95-9
Formule: C₂₄H₂₀F₃N₃O
Masse moléculaire:423.43

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

CDK8-IN-9 Chemical Structure

CAS No.: 2850253-95-9

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor with an IC₅₀ value of 48.6 nM. CDK8-IN-9 can inhibit tumor growth and is used in colorectal cancer studies^[1].

Voir tous les produits spécifiques à Isoform CDK :

Cellular Effect

Cell Line	Type	Value	Description	References
CT26	GI₅₀	4 μM Compound: 22	Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
GES1	GI₅₀	61.5 μM Compound: 22	Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
HCT-116	GI₅₀	4.9 μM Compound: 22	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
HT-29	GI₅₀	4.3 μM Compound: 22	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]
SW480	GI₅₀	2.1 μM Compound: 22	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36068975]

In Vitro

CDK8-IN-9 (compound 22) (0-100 μM, 48 h) can significantly inhibit cell proliferation and target CDK8 to inhibit the activation of the WNT/β-catenin pathway, thereby suppressing β-catenin-mediated transcriptional activity of TCF/ LEF^[1].
CDK8-IN-9 (compound 22) (0.5,1 and 2 μM, 24 h) induces G2/M and S-phase cell cycle arrest, thereby inhibiting cell proliferation rather than inducing apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HCT-116, HT-29, SW-480, CT-26 and GES-1 cells
Concentration:

0-100 μM
Incubation Time:

48 hours
Result:

Inhibited HCT-116, HT-29, SW-480, CT-26 and GES-1 cells with the GI₅₀ values of 4.9, 4.3, 2.1, 4.0 and 61.5 μM, respectively.

Cell Cycle Analysis^[1]

Cell Line:

HCT-116 cells
Concentration:

0.5, 1, and 2 μM
Incubation Time:

24 hours
Result:

Arrested cells in G2/M phase by 17%, 20.26% and 34.45% at concentrations of 0.5, 1, and 2 μM, respectively.
Showed a decrease in the G0/G1 phase and a slight increase in the S phase.

In Vivo

CDK8-IN-9 (compound 22) (p.o., 20, 40 and 80 mg/kg, daily, 3 weeks) significantly reduces in tumor volume and inhibits weight loss in mice at the concentration of 80 mg/kg in Balb/c mice infected with CT-26 murine colon cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague−Dawley rats^[1]
Dosage:

10 mg/kg or 5 mg/kg
Administration:

p.o. for 10 mg/kg and i.v. for 5 mg/kg

Result:

The pharmacokinetic parameters of CDK8-IN-9 (compound 22)

Parameters	t_1/2 (h)	T_max (h)	MRT (h)	C_max (μg/L)	AUC_0-∞ (μg/L·h)	CL (L/h/kg)	F (%)
10 mg/kg (po)	1.21	0.75	2.022	497.56	783.66	9.23	39.8
5 mg/kg (iv)	1.63	-	1.756	706.29	983.09	11.32	-

Related Protocols :

Chemical Information

CAS No. 2850253-95-9
Masse moléculaire 423.43
Formule C₂₄H₂₀F₃N₃O
SMILES

O=C(NC1=CC=C(C)C(C(F)(F)F)=C1)CCC2=CC=CC(C3=CN=C(NC=C4)C4=C3)=C2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Xing Xing Zhang, et al. Discovery of the Novel 1H-Pyrrolo[2,3-b]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer. J. Med. Chem.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis